MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Interview with Matt Thompson, MD
A look at what the United States and the United Kingdom can learn from each other, how to interpret the clinical trial data, and making endovascular technology more cost-effective.
Life Seal Vascular Appoints Dr. Matt Thompson as Chief Executive Officer
March 10, 2025—Life Seal Vascular Inc, announced the appointment of Matt Thompson, MD, as Chief Executive Officer (CEO).
The VIRTUE Registry
Matt Thompson, MB, FRCS, discusses the design and status of this registry and necessary outcomes to show that the Valiant endograft is a viable treatment option for patients with type B dissections.
Examining EVAR's Role in Rupture Care
By Frank R. Arko III, MD, and Matt Thompson, MD, FRCS
Experiences With the Valiant Thoracic Endograft
Evolved from the Talent, this new device design improves trackability and enables a lower force of deployment.
By Matt Thompson, MD, and Rob Morgan, MD
Coming Soon: TEVAR in the Ascending Aorta?
The emergence of endovascular therapy in this challenging anatomy as an alternative to open repair.
By Matt Thompson, MD, FRCS
The VIRTUE registry is designed to assess thoracic endografting with the Valiant Stent Graft System for the treatment of type B aortic dissections.
Chronic Aneurysmal Aortic Dissection
A staged hybrid procedure and a fenestrated endograft were used to treat this challenging presentation.
By R. M. Walkden, MRCS, FRCR; Rob A. Morgan, MRCP, FRCR; Ian Loftus, MD, FRCS; and Matt Thompson, MB, FRCS
Sponsored by Cook Medical
Endografts and the Aortic Arch: Zenith TX2 With Pro-Form
Control of endografts in the distal arch was difficult due to issues with conformability and accuracy—advances in graft technology may ensure a higher degree of technical success.
By Matt Thompson, MD, FRCS; Ian Loftus, MD, FRCS; and Rob Morgan, MRCP, FRCR
Sponsored by Endologix
The Ovation Abdominal Stent Graft Creates a Patient-Specific EVAR Seal in a Variety of Anatomies
With Salem M. George Jr, MD, FACS; Venkatesh Ramaiah, MD, FACS; and Matt Thompson, MD, FRCS
Endologix Announces Leadership Transition
January 7, 2025—Endologix LLC announced that John Liddicoat, MD, has been appointed as President and CEO, effective immediately.
EVAS FORWARD—Global Registry Supports Endologix's Nellix Device
April 29, 2015—Endologix, Inc. announced that updated clinical data from the company’s EVAS FORWARD—Global Registry were presented by Professor Matt Thompson, MD, at the Charing Cross Symposium being held April 28 to May 1 in London, United Kingdom.
TriVascular Begins OVATION Postmarket Study in Europe
April 9, 2011—TriVascular, Inc. (Santa Rosa, CA) announced the start of the European OVATION study at the 33rd annual Charing Cross International Symposium in London.
TriVascular Initiates OVATION Postmarket Registry in Europe
April 9, 2011—TriVascular, Inc. (Santa Rosa, CA) announced the start of the OVATION study at the 33rd annual Charing Cross International Symposium in London.
Endologix Appoints Graham Phillips as Chief Operating Officer
June 18, 2024—Endologix LLC announced the appointment of Graham Phillips as Chief Operating Officer, effective immediately.
TriVascular's OVATION Postmarket Registry Begins Enrollment
July 25, 2011—TriVascular, Inc. (Santa Rosa, CA) announced the commencement of enrollment in the OVATION study—a multicenter, prospective, European postmarket registry.
Endologix Receives CE Mark for Alto Abdominal Stent Graft System
August 5, 2020—Endologix Inc. announced that the company’s Alto abdominal stent graft system has received CE Mark approval in the European Union (EU) for endovascular aneurysm repair (EVAR) in abdominal aortic aneurysms (AAAs).
Endologix Announces Recall of Nellix EVAS System, Restricting Use to Prescreened Patients Within Current Indications
January 4, 2019—Endologix, Inc. announced a voluntary recall of all existing Nellix endovascular aneurysm sealing (EVAS) system inventory and the stoppage of unrestricted sales and use of the device, effective immediately.
European CE Mark Reinstated for Endologix's Nellix EVAS System
June 6, 2019—Endologix, Inc. announced that CE Mark certification for the company's Nellix endovascular aneurysm sealing (EVAS) system has been reinstated by GMED, the European Union Notified Body for the device, after an assessment of clinical evidence.
CE Mark Suspended for Endologix's Nellix System
January 22, 2019—Endologix, Inc. announced that the CE Mark for the Nellix endovascular aneurysm sealing system has been suspended by its Notified Body, GMED, after a voluntary recall and Field Safety Notification (FSN) issued by Endologix on January 4, 2019.
